key: cord-0859284-73jshcm9
authors: Saussez, Sven; Sharma, Shilpee; Thiriard, Anaïs; Olislagers, Véronique; Vu Duc, Inès; Le Bon, Serge‐D.; Khalife, Mohamad; Hans, Stephane; De Riu, Giacomo; Hopkins, Claire; Lechien, Jerome R.; Vaira, Luigi A.; Marchant, Arnaud
title: Predictive factors of smell recovery in a clinical series of 288 coronavirus disease 2019 patients with olfactory dysfunction
date: 2021-07-09
journal: Eur J Neurol
DOI: 10.1111/ene.14994
sha: 09461bc614c54bc8571273c83f6eb21d340b343c
doc_id: 859284
cord_uid: 73jshcm9

BACKGROUND AND PURPOSE: The aim was to evaluate potential predictive factors of smell recovery in a clinical series of 288 patients presenting olfactory dysfunction (OD) related to coronavirus disease 2019 (COVID‐19). Potential correlations were sought between epidemiological, clinical and immunological characteristics of patients and the persistence of OD at 60 days. METHODS: COVID‐19 positive patients presenting OD were prospectively recruited from three European hospitals. Baseline clinical and olfactory evaluations were performed within the first 2 weeks after OD onset and repeated at 30 and 60 days. In a subgroup of patients, anti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies were measured in serum, saliva and nasal secretions at 60 days. RESULTS: A total of 288 COVID‐19 patients with OD were included in the study. Two weeks after the onset of the loss of smell, 52.4% of patients had OD on psychophysical tests, including 113 cases (39.2%) of anosmia and 38 cases (13.2%) of hyposmia. At 60‐day follow‐up, 25.4% of the patients presented persistent OD. There was no significant correlation between sex, age, viral load on nasopharyngeal swab or COVID‐19 severity and poor olfactory outcome. In a subgroup of 63 patients, it was demonstrated that patients with poor olfactory outcomes at 60 days had lower levels of salivary and nasal immunoglobulin G (IgG) and IgG1, but similar levels of antibodies in the serum. CONCLUSIONS: No clinical markers predicted the evolution of OD at 60 days. Patients with poor olfactory outcome at 60 days had lower saliva and nasal antibodies, suggesting a role for local immune responses in the persistence of COVID‐19 related OD.

Olfactory dysfunction (OD) is one of the most frequent clinical manifestations of coronavirus disease 2019 (COVID- 19) , affecting more than 70% of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] [2] [3] [4] . In the vast majority of patients, these disorders completely subside within a few weeks [5] [6] [7] . However, the first long-term follow-up studies are showing a prevalence of persistent severe olfactory disturbances ranging between 4.5% and 11% 6 months after onset of symptoms [8] [9] [10] [11] . This frequency, given the high prevalence of infection in the population, means that in the near future there could be a very high number of subjects with long-term morbidity and a significant impact on quality of life [12] .

The pathogenesis of OD in COVID-19 seems to be linked to inflammatory responses involving support cells of the olfactory epithelium which, in some patients, can persist after the end of the infection with progressive damage to the sustentacular cells and olfactory neurons [7, [13] [14] [15] [16] [17] [18] . On this basis, corticosteroids were proposed to interrupt this pathological process before it affects cells that do not have regenerative capacity [19] [20] [21] [22] . To guide therapeutic interventions and avoid over-treatment of patients who will spontaneously recover, it is necessary to identify risk factors of persistent of OD. Unfortunately, no risk factor has been identified yet.

The aim of this multicentre study was to evaluate whether epidemiological, clinical and immunological characteristics of the patients correlate with the persistence of anosmia or severe hyposmia at 60 days from clinical onset.

This prospective study was approved by three Institutional Review Boards (CHU Saint-Pierre, Brussels, Belgium, CHUSP210207; Epicura, Baudour, Belgium, P2020011; Sassari University Hospital, Italy, PG/2021/5471). Patients provided written electronic or paper informed consent. and/or IgG). All patients were invited to perform olfactory training at least twice daily with >3 daily odours (e.g., coffee, perfume, essential oils) for each olfactory training session.

The following epidemiological data were collected through a standardized online questionnaire or medical records: gender, age, smoking and comorbidities. The following comorbidities were evaluated: hypercholesterolaemia, reflux, heart, respiratory, kidney, liver, autoimmune diseases, diabetes, neurological, hypertension, allergy, chronic rhinitis, chronic rhinosinusitis, depression, 

Subjective olfactory and gustatory functions were evaluated with the smell and taste component of the National Health and Nutrition Examination Survey, as previously described [9] . Psychophysical olfactory assessments were performed with the identification component of Sniffin' Sticks tests (Medisense, Groningen, Netherlands), which is a validated psychophysical olfactory test using 16 smell pens. Each pen is presented to individuals who have to choose the adequate smell patients with poor olfactory outcomes at 60 days had lower levels of salivary and nasal immunoglobulin G (IgG) and IgG1, but similar levels of antibodies in the serum.

No clinical markers predicted the evolution of OD at 60 days. Patients with poor olfactory outcome at 60 days had lower saliva and nasal antibodies, suggesting a role for local immune responses in the persistence of COVID-19 related OD.

COVID-19, IgG, IgG1, olfactory dysfunction, SARS-COV-2 | 3

between four given options. The final score ranges from 0 (none correctly identified) to 16 (all correctly identified). Normative values established normosmia as a score ranging between 12 and 16, hyposmia between 9 and 11 and anosmia between 0 and 8 [25] . 

Two groups of patients were identified having either a good evolution or a persistence of severe OD. The 'good olfactory outcome' group corresponds to patients presenting either a normal sniffing test (i.e., ≥12/16) at one of the tests carried out during the 2 months of follow-up (the sniffing test being performed at 15, 30 and 60 days of the onset OD, except for patients presenting a severe form of COVID-19 for whom the sniffing test was performed at 2 months) or a sniffing test ≥10 at 60 days. The 'poor olfactory outcome' group corresponds to patients with a score between 0 and 9 on the sniffing test carried out 2 months after the onset of symptoms.

Recombinant SARS-CoV-2 spike antigens S1, S2 and RBD, purchased from SinoBiological (40591-VO8H, 40590-VO8B and 40592-VNAH respectively), and nucleocapsid protein (NP) (kindly provided by André Matagne, University of Liège) were covalently coupled to fluorescent magnetic beads (Luminex Corporation) by a two-step carbodiimide reaction, with 5 µg of antigens for F I G U R E 1 The flow chart of our study including 288 COVID-19 patients with olfactory dysfunction (OD). From 22 March 2020 to 15 November 2020, patients with a confirmed diagnosis of COVID-19 and OD confirmed by psychophysical tests were recruited within 2 weeks of onset of symptoms in three European hospitals, in Belgium and Italy. Baseline clinical and semi-objective olfactory evaluations of patients suffering from mild COVID-19 were performed within the first 2 weeks after OD onset and repeated 1 and 2 months later. For patients suffering from severe COVID-19, it was not possible to perform semi-objective olfactory evaluations during hospitalization (due to the sanitary situation) but baseline clinical and subjective olfaction evaluations were assessed. Then, semi-objective olfactory evaluations were assessed at 2 months after OD onset. Patients from Epicura Hospital (Baudour, Belgium) participated in a nested study which aimed to assess the antibody responses to SARS-CoV-2 in the serum, saliva and nasal secretions 2 months after COVID-19 onset 1 million beads. 1000 beads/antigen/well diluted in assay wash buffer (PBS-1X, 0.1% BSA, 0.05% Tween 20, pH 7.4) was used for antibody screening. Based on preliminary experiments, the serum/ mucosal fluid dilution giving the best signal-to-noise ratio for IgG, IgG1 and IgG3 was 1/200 and 1/50 for IgA. PBS-diluted serum/ mucosal fluid samples were incubated for 2 h at room temperature on an orbital shaker with antigen-coupled beads. Antigen-specific antibody titres were detected using a phycoerythrin-coupled detection antibody for each subclass and isotype, namely IgG, IgG1, 

Statistical analyses were performed using the Statistical Package for the Social Sciences for Windows version 22.0 (IBM Corp.).

According to the type of outcomes, the following tests were used to compare severity groups: Kruskal-Wallis, Fisher's exact test and Mann-Whitney U test. The pre-to post-intervention changes in Sniffin' Sticks tests were evaluated within group with the Mann-Whitney U test whilst the inter-group differences were assessed through the differences between Sniffin' Sticks test scores by means of the Wilcoxon signed-rank test. Multivariate analysis was used to study the associations between outcomes.

In all, 288 COVID-19 patients were included in the study ( Table 2 ). The mean olfactory score at the end of the observation period was 12.7 ± 2.8. Overall, 34 subjects (11.8%) therefore presented a poor outcome (i.e., anosmia or severe hyposmia) at 60 days. Table 3 , there was no significant association between poor olfactory outcome and female gender (odds ratio were not significantly different in patients with good or poor olfactory outcome at 2 months (Figure 2a-d) .

The 

With 152 million cases of COVID-19 ( people will present with OD. Amongst these, it seems crucial to be able to detect patients at risk of prolonged anosmia or hyposmia.

In this regard, it has recently been described in a clinical series of 751 COVID-19 patients with OD that 37% still reported a persistent subjective loss of smell and 14% reported partial recovery after a mean follow-up of 47 days [28] . Using objective olfactory evaluations, it was shown also in a clinical series of 118 COVID-19 patients that 15% did not fully recover olfaction at 60 days [9] . The first 6-month follow-up studies reported a prevalence of severe and persistent OD ranging between 4.5% and 11% [8] [9] [10] [11] 29] . This high incidence of OD persistence calls for therapies that could prevent this long-term morbidity. Considering the likely role of progressive inflammatory damage to the olfactory epithelium [14, 16] , these therapies could potentially be more effective if started as early as possible after onset of symptoms [18] [19] [20] [21] [22] . However, some authors reported that micro-haemorrhage might be another cause of persistent OD [30] . The use of corticosteroids in these patients can be detrimental due to their anti-angiogenic effect which can worsen the vascular supply resulting in induced hypoxia. Moreover, as many patients recover quickly, guidelines published on the management of COVID-19 OD propose use of oral corticosteroids as an option in those with symptoms persistent for more than 2 weeks [31] . Guiding the best use of these 'optional' interventions requires the identification of predictive factors associated with poor functional recovery.

However, no clinical, epidemiological or laboratory risk factors have yet been identified [32, 33] . In this study including 288 patients with COVID-19 OD, it is confirmed that no clinical or epidemiological factor predicts the evolution of OD at 2 months. Patients with OD must therefore be counselled on the potential risks versus benefits of corticosteroids and the chance of spontaneous recovery before use of corticosteroids; this remains a difficult decision for both clinicians and patients and is an area where further research is needed to guide decision making.

Based on the lack of relationship between severity and duration of OD and systemic inflammatory markers, it has been hypothesized that local factors are involved in the persistence of OD [15] . Whilst information on systemic immunity to SARS-CoV-2 continues to rapidly accrue [37, 38] , the role of mucosal immunity within the nasal cavities and the upper respiratory tract, the primary site of SARS-CoV-2 infection and replication, remains largely unexplored. Butler et al. [39] and Cervia et al. [40] found an inverse correlation between the levels of serum and nasal antibody levels and severity of COVID-19. Patients with severe disease had higher serum antibody levels whilst nasal antibodies were higher in milder disease.

Our study indicates that patients with good olfactory outcomes at 60 days had higher levels of salivary and nasal IgG and IgG1 compared to patients with poor outcomes. Interestingly, no association was observed with the levels of serum antibodies, suggesting a role for local immune response. Although IgG is often considered as a systemic antibody, it is increasingly recognized that it is also produced at the mucosal level and can participate in mucosal immunity to pathogens [41] . In contrast to IgG, the levels of mucosal IgA were not different in the two groups. This dissociation between the two types of antibodies is intriguing and could be related to a more transient production of

IgA compared to IgG.

The inverse association between local IgG levels and duration of OD suggests a role for antibodies in the control of SARS-CoV-2 replication and prevention of epithelial damage. Indeed, studies have shown that in patients with mild infection and olfactory impairment, viral clearance was delayed compared to patients with normal olfaction [42] . Longitudinal studies are needed to characterize the antibody response to SARS-CoV-2 soon after the onset of symptoms F I G U R E 3 Relationship between OD recovery and salivary IgG (a), IgG1 (b), IgG3 (c) and IgA (d) responses to SARS-CoV-2 antigens in a subgroup of 63 patients (15 patients with persistent severe OD vs. 48 with good olfactory outcomes). (a) Patients with poor olfactory outcome had lower levels of saliva S1 and RBD IgG than patients with good olfactory outcomes. Patients from the poor olfactory outcome group also presented lower levels of saliva S1, RBD, S2 and NP IgG1 compared to the good olfactory outcome group (b). No association between olfactory outcome and salivary IgG3 (c) or IgA (d) responses to SARS-CoV-2 antigens was observed. The results are expressed as median fluorescence intensity (MFI). Red box plots correspond to patients with poor olfactory outcomes at 60 days whereas black box plots correspond to patients with good olfactory outcomes at 60 days. ns, not significant. *p < 0.05; **p < 0.01 and to identify the predictive value of these parameters for the duration of OD.

Our study has some limitations. As already mentioned, there

were only a small number of patients with poor olfactory outcome and further studies with larger case series will be needed to confirm these results. Secondly, the 60-day follow-up is still too short to declare the OD permanent, and these patients may still recover. However, other authors have reported that improvements in olfactory scores tend to become non-significant 2 months after clinical onset [10, 11] . 

In patients with a loss of smell related to COVID-19, no clinical markers predicted the evolution of symptoms at 60 days. Patients with poor olfactory outcome at 60 days had lower saliva and nasal antibodies, suggesting a role for local immune responses in the persistence of COVID-19 related OD.

The study was co-funded by the F.R.S. 

None of the authors has a financial interest in any of the products, devices or drugs mentioned in this paper.

Sven Saussez: Conceptualization (equal); data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); project administration (equal); supervision (equal); validation (equal);

writing-original draft (equal); writing-review and editing (equal).

Shilpee Sharma: Data curation (equal); investigation (equal); methodology (equal); resources (equal). Anais Thiriard: Data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); software (equal). Veronique Olislagers: Data curation (equal); resources (equal). Ines Vu Duc: Data curation (equal); resources F I G U R E 4 Relationship between OD recovery and nasal IgG (a), IgG1 (b), IgG3 (c) and IgA (d) responses to SARS-CoV-2 antigens in a subgroup of 66 patients (15 patients with persistent severe OD vs. 51 with good olfactory outcomes at 60 days). (a) Individuals from the poor olfactory outcome group had lower levels of nasal RBD, S2 and NP IgG than patients from the good olfactory outcome group. The poor olfactory outcome group also had lower levels of nasal S1 and S2 IgG1 than the good olfactory outcome group (b). A similar trend was observed with nasal RBD and NP IgG3 (c). No association was observed between olfactory recovery and nasal IgA response (d). The results are expressed as median fluorescence intensity (MFI). Red box plots correspond to patients with poor olfactory outcomes at 60 days whereas black box plots correspond to patients with good olfactory outcomes at 60 days. ns, not significant. *p < 0.05

Mohamad Khalife: Data curation (supporting); investigation (supporting)

Conceptualization (supporting); data curation (supporting). Claire Hopkins: Writing-review and editing (supporting)

Conceptualization (equal); data curation (equal)

Luigi Vaira: Conceptualization (equal)

data curation (equal); investigation (equal); methodology (equal)

writing-original draft (equal); writing-review and editing (equal)

Arnaud Marchant: Conceptualization (equal); formal analysis (equal)

funding acquisition (equal); writing-review and editing (equal). accordance with the ethical standards of the institutional and/ or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards

More than smell-COVID-19 is associated with severe impairment of smell, taste, and chemesthesis

Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection

Epidemiological, otolaryngological, olfactory and gustatory outcomes according to the severity of COVID-19: a study of 2579 patients

Psychophysical evaluation of the olfactory function: European multi-center study on 774 COVID-19 patients

Severity of anosmia as an early symptom of COVID-19 infection may predict lasting loss of smell

Recovery rate and factors associated with smell and taste disruption in patients with coronavirus disease 2019

Smell and taste recovery in coronavirus disease 2019 patients: a 60-day objective and prospective study

Six-month psychophysical evaluation of olfactory dysfunction in patients with COVID-19

Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients

Six-month smell and taste recovery rates in COVID-19 patients: a prospective psychophysical study

Long-term follow-up of olfactory and gustatory dysfunction in COVID-19: 6 months case-control study of health workers

Association between olfactory function and quality of life in patients with olfactory disorders: a multicenter study over 760 patients

Anosmia in COVID-19: a bumpy road to establishing a cellular mechanism

Inflammatory olfactory neuropathy in two patients with COVID-19

Proinflammatory cytokines in the olfactory mucosa result in COVID-19 induced anosmia

Olfactory epithelium histopathological findings in long-term COVID-19 related anosmia

ACE2 and TMPRSS2 expressions in head and neck tissues: a systematic review

Potential pathogenesis of ageusia and anosmia in COVID-19 patients

Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: a randomized controlled trial

Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell

Efficacy of corticosteroid therapy in the treatment of long-lasting olfactory disorders in COVID-19 patients

Short-term efficacy and safety of oral and nasal corticosteroids in COVID-19 patients with olfactory dysfunction: a European multicenter study

Validity and reliability of the COVID-19 symptom index, an instrument evaluating severity of general and otolaryngological symptoms

Psychometric and clinimetric validity of the 20-Item Sino-Nasal Outcome Test

Updated Sniffin' Sticks normative data based on an extended sample of 9139 subjects

Characteristics of COVID-19 infection in Beijing

Prevalence of olfactory dysfunction in coronavirus disease 2019 (COVID-19): a meta-analysis of 27,492 patients

Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak

Six month follow-up of selfreported loss of smell during the COVID-19 pandemic

Olfactory bulb MRI and paranasal sinus CT findings in persistent COVID-19 anosmia

Management of new onset loss of sense of smell during the COVID-19 pandemic -BRS Consensus Guidelines

Correlations between IL-6 serum level and olfactory dysfunction severity in COVID-19 patients: a preliminary study

Systemic inflammatory markers and psychophysical olfactory scores in COVID-19 patients. Is there any correlation?

COVID-19 viral load in the severity and recovery from olfactory and gustatory function

COVID-19-associated olfactory dysfunction reveals SARS-CoV-2 neuroinvasion and persistence in the olfactory system

Interferon-α2b treatment for COVID-19

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescent from COVID-19 infection

Distinct features and functions of systemic and mucosal humoral immunity among SARS-CoV-2 convalescent individuals

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19

Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA

Acute onset olfactory/ taste disorders are associated with a high viral burden in mild or asymptomatic SARS-CoV-2 infections

How to cite this article